CONMED (NYSE:CNMD) Price Target Raised to $42.00

CONMED (NYSE:CNMD) had its target price boosted by Wells Fargo & Company from $41.00 to $42.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

CNMD has been the topic of several other reports. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a research report on Thursday. Zacks Research downgraded CONMED from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 1st. JPMorgan Chase & Co. lowered their price objective on CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. Piper Sandler reduced their target price on shares of CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $52.83.

CONMED Stock Performance

CNMD opened at $38.30 on Thursday. The company’s 50 day moving average is $41.33 and its 200 day moving average is $46.33. The company has a current ratio of 2.10, a quick ratio of 0.95 and a debt-to-equity ratio of 0.85. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.66 and a beta of 0.96. CONMED has a 12-month low of $35.37 and a 12-month high of $74.70.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, January 28th. The company reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.11. CONMED had a net margin of 3.42% and a return on equity of 14.36%. The business had revenue of $373.20 million for the quarter, compared to the consensus estimate of $366.88 million. During the same period last year, the firm earned $1.34 earnings per share. The company’s quarterly revenue was up 7.9% on a year-over-year basis. On average, equities research analysts predict that CONMED will post 4.35 EPS for the current year.

Hedge Funds Weigh In On CONMED

A number of hedge funds and other institutional investors have recently modified their holdings of CNMD. New York State Teachers Retirement System increased its holdings in CONMED by 1.6% in the 4th quarter. New York State Teachers Retirement System now owns 45,592 shares of the company’s stock valued at $1,851,000 after acquiring an additional 728 shares during the last quarter. Comerica Bank increased its holdings in shares of CONMED by 83.1% in the fourth quarter. Comerica Bank now owns 56,271 shares of the company’s stock worth $2,285,000 after purchasing an additional 25,533 shares during the last quarter. Sanctuary Advisors LLC lifted its position in shares of CONMED by 9.8% in the fourth quarter. Sanctuary Advisors LLC now owns 7,335 shares of the company’s stock worth $298,000 after buying an additional 652 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of CONMED by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company’s stock worth $149,588,000 after buying an additional 73,533 shares in the last quarter. Finally, HB Wealth Management LLC bought a new position in CONMED during the fourth quarter valued at approximately $649,000.

Key CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.